Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: Antiemetic prescriptions and incidence of emesis

Tumori

Volumn 90, Issue 1, 2004, Pages 103-106

  De Angelis, Verena ^a  

^a ASL 2   (Italy)

Author keywords

5 HT3 antagonists; Antiemetic prescriptions; Intermediate emetogenic chemotherapy

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; GEMCITABINE; IRINOTECAN; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRESCRIPTION; PROPHYLAXIS; PROSPECTIVE STUDY; VOMITING;

EID: 2142766793     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000121     Document Type: Article

References (3)

1. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG: Recommendations for the use of antiemetics: evidence based clinical practice guidelines. J Clin Oncol, 17: 2971-2994, 1999.
2. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol, 9: 811-819, 1998.
3. De Angelis V, Roila F, Patoia L, Lopez M, Cetto G.L, Sabbatini R, Carreca I, Manente P, Del Favero A: Impact on antiemetic prescriptions of the Consensus Conference and of an expert's visit to oncological centers. Proc ASCO, 19: 606A (abst 2386), 2000.